Around 30 million adults in the United States have atherosclerotic cardiovascular disease (ASCVD).
Slightly more than half of them, 16 million, take statins to help lower their cholesterol. However, many are still not at their recommended target range for cholesterol levels.
Leqvio (inclisiran), a medication from Novartis recently approved by the Food and Drug Administration (FDA), might help lower cholesterol levels with only 2 doses per year.
Statins work by blocking substances that your body needs to make cholesterol. These medications typically must be taken at least once a day, some twice a day. Statins help by:
People with low-density lipoproteins (LDL), frequently called “bad cholesterol,” with 190 mg/dL or higher, often benefit from daily statins.
If you had a heart attack in the past, your doctor might recommend statins, even if you don’t have high cholesterol.
One of the main reasons statins are not always effective is because people often tend to have a difficult time adhering to the medication schedule. This is frequently because of the cost of the medication, its side effects, or a person’s lack of accessibility to prescription drugs.
However, not taking statins regularly is associated with significant increases in deaths from cardiovascular disease.
Leqvio is an adjunct treatment to a balanced diet and statins for lowering LDL.
People take an initial dose, another dose in 3 months, and then doses twice a year.
Three recent studies report LDL reductions between 40 percent and 51 percent when compared to a placebo for certain people with ASCVD who take statins.
Statins, nonetheless, will remain as first-line treatments.
“Leqvio works differently than other cholesterol treatments,” said Dr. Norman Lepor, FACC, a clinical investigator in the phase 3 clinical program, in a Novartis statement. “With twice-yearly dosing, it is a compelling option for millions of people with ASCVD who have a difficult time reaching their LDL-C target.”
The company statement said the medication works by improving the liver’s natural ability to prevent the production of a protein that keeps cholesterol levels high. It is a subcutaneous injection given by a qualified healthcare professional.
Because of the dosing schedule, experts say Leqvio may be helpful for people having difficulty sticking to a regular medication schedule.
“Leqvio is a game-changer in the world of cardiovascular disease treatment,” said Dr. Spencer Kroll, FNLA, an internal medicine specialist and a nationally recognized cholesterol and lipid disease expert.
“It leads to profound reductions in serum LDL levels,” Kroll told Healthline. “Multiple studies have found that the lower the LDL, the lower the cases of recurrent cardiovascular events in high-risk patients.”
Leqvio is an add-on treatment that works alongside diet changes and statins to manage cholesterol.
The FDA approved it for adults with heterozygous familial hypercholesterolemia or clinical ASCVD.
People with mild, moderate, or severe kidney impairment can take Leqvio. People with mild or moderate liver impairment can also take Leqvio.
There are no current studies of Leqvio in people with severe liver impairment.
There is currently no data on the use of Leqvio during pregnancy for risk of congenital disabilities, miscarriage, or adverse maternal or fetal outcomes.
Until further information is known, the recommendation is that people who are pregnant should stop taking the medication.
Some people experienced irritation at the injection site. Other side effects include:
About 2 percent of people stopped taking Leqvio because of adverse reactions.
The Healthline News team is committed to delivering content that adheres to the highest editorial standards for accuracy, sourcing, and objective analysis. Every news article is thoroughly fact-checked by members of our Integrity Network. Furthermore, we have a zero-tolerance policy regarding any level of plagiarism or malicious intent from our writers and contributors.
All Healthline News articles adhere to the following standards:
- All referenced studies and research papers must be from reputable and relevant peer-reviewed journals or academic associations.
- All studies, quotes, and statistics used in a news article must link to or reference the original source. The article must also clearly indicate why any statistics presented are relevant.
- All content related to new treatments, drugs, procedures, and so on must clearly describe availability, pricing, side effects, treatment target (e.g., HER2+), known interactions, and off-label use, if appropriate.
- All news articles must include original commentary from at least two qualified sources with appropriate credentials and links to relevant associations or published works.
- Any potential conflicts of interest related to a study or source must be clearly indicated to the reader.
- All news articles must include appropriate background information and context for the specific condition or topic.